Pharma-bio Serv, INC

Pharma-Bio Serv announced improved revenues and net income for the quarter ended April 30, 2026, driven by strategic market focus and cost management.

Pharma-Bio Serv, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of Irving Wiesen and the ratification of its independent auditors.

Pharma-Bio Serv, Inc. announced a modest profit of $32,860 for the quarter ended January 31, 2026, despite a $0.2 million decrease in revenues to $2.3 million.

Pharma-Bio Serv announced full-year 2025 results, reporting a revenue decrease but an improved net loss, alongside a special dividend declaration.

Pharma-Bio Serv, Inc. announced revenues of $2.0 million and a net loss of $0.2 million for the three months ended July 31, 2025, alongside strategic cost streamlining efforts.

Pharma-Bio Serv, Inc. announced a significant return to profitability for the quarter and six months ended April 30, 2025, driven by strategic focus on high-margin projects.

Pharma-Bio Serv, Inc. announced its financial results for the second quarter of fiscal year 2026, reporting an increase in net income and revenues, driven by growth in its Puerto Rico consulting segment.

Pharma-Bio Serv, Inc. reported a significant increase in net income for the first quarter of fiscal year 2026 despite a slight decline in overall revenues, driven by improved gross profit margins and higher other income.

Pharma-Bio Serv, Inc. reported a significantly reduced net loss for the nine months ended July 31, 2025, driven by improved gross profit margins and reduced operating expenses, despite a slight revenue decline.

Pharma-Bio Serv, Inc. reported a significant turnaround in its financial performance for the second quarter and first six months of fiscal year 2025, achieving net income driven by robust European market expansion and enhanced gross profit margins, despite revenue declines in other key regions.

Pharma-Bio Serv, Inc. reports a net income of $8,536 for the quarter ended January 31, 2025, a significant improvement compared to a net loss of $270,719 in the same period last year, driven by increased gross profit margins in the European market.

Pharma-Bio Serv experienced a significant decrease in revenue and a net loss for the third quarter of 2024, primarily due to reduced project activity in key markets.

Pharma-Bio Serv, Inc. filed an amendment to its 2025 annual report to update information on directors, executive compensation, security ownership, related party transactions, and principal accountant fees.

Pharma-Bio Serv, Inc. reported a significantly reduced net loss of $0.1 million for fiscal year 2025, driven by strong European market growth and improved gross profit margins, despite an overall revenue decline.

Pharma-Bio Serv, Inc. files an amendment to its annual report on Form 10-K to include information required by Items 10 through 14 of Part III, focusing on directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Pharma-Bio Serv's fiscal year 2024 saw a significant revenue decrease due to project declines in key markets, resulting in a net loss.

Pharma-Bio Serv, Inc. has filed an amendment to its annual report on Form 10-K to include required information regarding directors, executive compensation, and other corporate governance matters.

Pharma-Bio Serv's annual report reveals a decrease in revenue for fiscal year 2023, but an increase in net income due to improved gross profit margins and other income.

Howard Spindel, a Director of Pharma-Bio Serv, Inc., reported a transaction in 42,504 shares of common stock on June 9, 2026.

Pharma-Bio Serv's Chairman, Kirk Wheeler Michel, acquired 20,000 stock options with an exercise price of $0.54, vesting in two equal installments.

Pharma-Bio Serv Director Dov Perlysky acquired 20,000 stock options with an exercise price of $0.54, vesting in two equal installments.

Pharma-Bio Serv, Inc. Director Howard Spindel was granted 20,000 stock options with an exercise price of $0.54, vesting over two years.

Pharma-Bio Serv Director Irving L Wiesen was granted 20,000 stock options with an exercise price of $0.54, vesting in two equal installments.

Kirk Wheeler, a director at Pharma-Bio Serv, acquired 20,000 stock options on January 10, 2025.

Pharma-Bio Serv, Inc. has issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled for May 15, 2026.

Pharma-Bio Serv will hold its annual stockholders meeting on May 15, 2025, to vote on director election, auditor ratification, executive compensation, and other matters.

Pharma-Bio Serv, Inc. is holding its annual meeting of stockholders on May 2, 2024, to vote on the election of directors, ratification of auditors, and an amendment to the long-term incentive plan.